3 Stocks Boosting The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 25 points (-0.1%) at 18,080 as of Tuesday, May 12, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,119 issues advancing vs. 1,860 declining with 154 unchanged.

The Drugs industry currently sits down 0.2% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Opko Health ( OPK), up 3.1%, Sanofi ( SNY), up 1.0% and Gilead ( GILD), up 0.7%. On the negative front, top decliners within the industry include NewLink Genetics ( NLNK), down 28.1%, DepoMed ( DEPO), down 18.1%, Endo International ( ENDP), down 2.8%, Mylan ( MYL), down 1.6% and AstraZeneca ( AZN), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Dr Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Dr Reddy Laboratories is up $1.25 (2.4%) to $54.26 on heavy volume. Thus far, 224,176 shares of Dr Reddy Laboratories exchanged hands as compared to its average daily volume of 298,800 shares. The stock has ranged in price between $53.14-$54.36 after having opened the day at $53.55 as compared to the previous trading day's close of $53.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr Reddy Laboratories has a market cap of $9.0 billion and is part of the health care sector. Shares are up 5.1% year-to-date as of the close of trading on Monday. Currently there are no analysts who rate Dr Reddy Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Dr Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Dr Reddy Laboratories Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Receptos ( RCPT) is up $10.56 (6.8%) to $166.59 on average volume. Thus far, 405,590 shares of Receptos exchanged hands as compared to its average daily volume of 801,600 shares. The stock has ranged in price between $153.87-$166.90 after having opened the day at $155.16 as compared to the previous trading day's close of $156.03.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Receptos has a market cap of $4.9 billion and is part of the health care sector. Shares are up 25.6% year-to-date as of the close of trading on Monday. Currently there are 3 analysts who rate Receptos a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Receptos as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Receptos Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Intercept Pharmaceuticals ( ICPT) is up $11.76 (4.2%) to $292.03 on heavy volume. Thus far, 425,739 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 562,500 shares. The stock has ranged in price between $280.00-$293.47 after having opened the day at $280.00 as compared to the previous trading day's close of $280.27.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $6.7 billion and is part of the health care sector. Shares are up 77.3% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Intercept Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices